2024 • Volume 48 • https://doi.org/10.33321/cdi.2024.48.39 • Electronic publication date: 17/07/2024

To B or not to B: how the hepatitis B surveillance case definition can misdirect public health actions

Anna B Pierce, Simon Crouch, Adrian Alexander, Joe Sasadeusz, Edura Jalil, Victor Au Yeung, Aswan Tai, Rhonda L Stuart

# Abstract

Surveillance case definitions are utilised to understand the epidemiology of communicable diseases and to inform public health actions. We report a case of hepatitis B infection that meets the case definition for newly acquired infection. However, further investigation revealed that this was most likely past resolved hepatitis B infection with subsequent reactivation secondary to immunosuppression, rather than a newly acquired infection. This case highlights the importance of thorough case and clinician interviews, in combination with detailed assessment of pathology results in collaboration with treating clinicians, to determine the most appropriate public health actions.

Keywords: Hepatitis B; surveillance; case definition; transmission; reactivation

# Introduction

The hepatitis B virus (HBV) is transmitted via percutaneous or mucosal exposure to blood or bodily fluids from an infected person. Transmission has been confirmed to occur from mother to child; via non-sexual household contact; sexual contact; needle sharing; and occupational exposures in the healthcare setting.1

Surveillance case definitions are utilised to understand the epidemiology of communicable diseases and to inform public health actions. The Communicable Disease Network Australia (CDNA) has two surveillance case definitions for confirmed cases of hepatitis B – one for newly acquired cases (Box 1) and one for unspecified cases.2

Box 1: Hepatitis B (newly acquired) CDNA surveillance case definitiona

A conﬁrmed case requires laboratory deﬁnitive evidence only.

Laboratory deﬁnitive evidence

Detection of hepatitis B surface antigen (HBsAg) in a patient shown to be negative within the last 24 months

OR

Detection of HBsAg and immunoglobulin M (IgM) to hepatitis B core antigen, except where there is prior evidence of hepatitis B infection

OR

Detection of hepatitis B virus by nucleic acid testing, and IgM to hepatitis B core antigen, except where there is prior evidence of hepatitis B infection

a Source: reference 2.

# Case history

In May 2023, the South East Public Health Unit (SEPHU) in Melbourne, Victoria received a laboratory notification of hepatitis B infection for further investigation. The case was a woman in her seventies who was tested for hepatitis B in April 2023 as a potential source for a needlestick injury. She was in hospital following surgery performed on 3 April 2023 and required a blood transfusion on 8 April 2023. The case had negative hepatitis B serology in February 2022, thus meeting the hepatitis B newly acquired case definition (Table 1).

The case has a history of chronic lymphocytic leukaemia (CLL) and was treated with ibrutinib between 2015 and 2021. Due to disease relapse, she was switched to venetoclax and rituximab in February 2022. Hepatitis B serology was repeated in February 2022 as baseline screening prior to commencing rituximab.

The case was born in Greece and emigrated to Australia in 1970. She has no record of ever being vaccinated for hepatitis B.

Table 1: Hepatitis B test results at different timepoints

| Test | Timepoint | | | |
| --- | --- | --- | --- | --- |
| 8 July 2014 | 18 February 2022 | 23 April 2023 | 25 April 2023 |
| Hepatitis B surface antigen (HBsAg) | Negative | Negative | Positive | Positive |
| Hepatitis B core antibody – total  [anti-HBc (Total)] |  | Negative | Negative | Negative |
| Hepatitis B core antibody – IgM  [anti-HBc (IgM)] |  |  | Negative |  |
| Hepatitis B surface antibody (anti-HBs)a |  |  |  | 0 mIU/ml |
| Hepatitis B e antigen (HBeAg) |  |  |  | Positive |
| Anti-HBe (Hepatitis B antibody) |  |  |  | Negative |
| HBV viral loada |  |  | 639 X106 IU/ml | 827 x 106 IU/ml |

a IU: infectious units.

# Exposure investigation

The public health actions for a newly acquired case of hepatitis B include an investigation to determine the likely exposure source for the case, in order to identify other potential exposures and opportunities to interrupt further transmission.2 Traceback should be up to six months before the most recent negative test result.

Interviews conducted with the case’s general practitioner and next of kin did not identify any clear sources of infection. Testing hepatitis B serology on other family members, including siblings in Greece, was recommended but no results were available.

The case’s family believed she acquired the infection from the blood transfusion, but a thorough investigation by Lifeblood quickly excluded this. The recent hip surgery was also most unlikely as a source of infection: transmission from healthcare workers in Australia is rare, and the incubation period for detection of HBsAg in the blood following exposure is usually 4–10 weeks.3,4

# Discussion

This case raises several issues pertaining to diagnosis, clinical management and public health follow-up of newly diagnosed hepatitis B infection in an immunocompromised host.

From a clinical perspective, there was no evidence that the case had a history of hepatitis B infection. HBsAg was negative in 2014 prior to commencing immunosuppressive therapy with ibrutinib for CLL, and again in February 2022 prior to switching to rituximab for CLL. Despite recommendations that HBsAg, anti-HBc and anti-HBs are all performed when testing for hepatitis B infection, it is unclear why the patient was only tested for anti-HBc in 2022 and anti-HBs testing was never performed.5

Rituximab, a monoclonal anti-CD20 antibody, is associated with high risk of hepatitis B reactivation and the US Food and Drug Administration has issued a boxed warning regarding increased risk of hepatitis B reactivation in patients with positive anti-HBs or anti-HBc.6,7 It is recommended that such patients receive preventive antiviral therapy with tenofovir or entecavir.5,8 Based on the February 2022 serology result, there was no indication to commence antiviral therapy. The patient’s last dose of rituximab was in July 2022 and liver function tests remained normal throughout this time. Testing as the source of a healthcare worker needlestick injury likely aided early diagnosis of hepatitis B reactivation.

There are several reasons to suggest that it is much more likely that this case had past resolved hepatitis B infection with subsequent reactivation secondary to immunosuppression, rather than a newly acquired infection. Firstly, no clear exposure sources were identified. In addition, the case was born prior to the introduction of hepatitis B immune globulin (HBIG) and HBV vaccination. Endemic rates of hepatitis B infection in the case’s birthplace, Greece, are known to be high: prevalence of HBV infection was reported at over 18% in Greek army recruits in 1973, and 44% of patients admitted to a cancer unit in Greece during 1986–1995 had at least one HBV marker positive.9,10 The case had also been on B cell depleting therapy for many years, supporting the hypothesis that the 2022 results could represent a false negative core antibody result.

Notwithstanding the above, this case does meet the surveillance case definition criteria for a newly acquired hepatitis B infection. While brief consideration was given to the blood transfusion as a potential exposure source, this was considered highly unlikely as all blood products in Australia are screened for hepatitis B with nucleic acid testing (NAT). Since this was instituted in 2010, there has only been one case of probable transmission of hepatitis B via blood transfusion in Australia, and the risk of transmission is estimated to be less than one in one million units transfused.11 Likewise, the recent hip surgery is an unlikely source given the timeframe and the rarity of transmission of hepatitis B from healthcare workers to patients in Australia.12 It should be noted that although there is no mandated testing of healthcare workers in Australia for eligibility to work, it is necessary to comply with the CDNA National Guidelines for healthcare workers living with blood borne viruses.13

Although we cannot prove that this case did have past hepatitis B infection, the combination of her epidemiological risk, her clinical history that includes haematological malignancy, immunosuppressive therapy and hypogammaglobulinaemia, and the lack of a likely exposure source all suggest that this is most likely reactivation rather than a newly acquired case. This is further supported by the fact the anti-HBc (both total and IgM) remained negative on the most recent testing.

There are several issues that stem from this case. Firstly, it is critical to assess prior HBV exposure with all three markers: HBsAg, anti-HBc and anti-HBs (the latter is an important additional marker in non-immunised individuals). It also highlights the issues with screening and testing of immunocompromised patients who may have low or absent antibody levels. And finally, it raises the question of the need for ongoing follow-up and potential regular screening for HBV reactivation in patients on rituximab with negative hepatitis B serology who are from a country with a high prevalence of hepatitis B. If all three serological markers were not tested prior to the development of immunosuppression, then monitoring with liver function tests, HBV DNA and HBsAg every 1–3 months, as recommended for those with resolved infection not on prophylaxis, may be considered.14 An alternative approach would be to simply monitor liver function tests and consider hepatitis B infection if there is an unexplained rise in alanine aminotransferase (ALT).5

# Conclusion

The current surveillance case definition for acute hepatitis B has limitations and may incorrectly include people with HBV reactivation. This is of particular relevance in the setting of immunosuppression, and if prior HBV exposure is not assessed with all three markers (HBsAg, anti-HBc and anti-HBs). This case meets the surveillance case definition for newly acquired hepatitis B; however, their clinical and public health management were both based on an assessment that this is likely reactivation rather than a true new infection.

While consistent and strict application of surveillance case definitions is appropriate to ensure trend data is accurate at a population level, public health practitioners should be alert to the possibility that some confirmed cases of newly acquired hepatitis B may not represent a recent transmission event. Thorough case and clinician interviews, in combination with detailed assessment of pathology results in collaboration with treating clinicians, are essential to determine the most appropriate public health actions.

# Author details

Dr Anna B Pierce,1,2,3,4

Dr Simon Crouch,1,3

Dr Edura Jalil,1,3

Dr Adrian Alexander,4

Dr Joe Sasadeusz,5,6

Dr Victor Au Yeung,1,3,7

Dr Aswan Tai,1

Dr Rhonda L Stuart.2,3,8

1. South East Public Health Unit, Monash Health, Clayton, Victoria, Australia.
2. Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
3. Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
4. Department of Infectious Diseases, The Alfred, Melbourne, Victoria, Australia.
5. Victorian Infectious Diseases Service at The Royal Melbourne Hospital, Victoria, Australia.
6. Peter Doherty Institute for Infection and Immunity, The University of Melbourne and The Royal Melbourne Hospital, Victoria, Australia.
7. General Medicine, Monash Health, Clayton, Victoria, Australia.
8. Director, South East Public Health Unit, Monash Health, Clayton, Victoria, Australia.

Corresponding author

Dr Anna B Pierce

Address: South East Public Health Unit, Monash Health, Clayton, Victoria, Australia

Phone: +61 407 434 471

Email: anna.pierce@monashhealth.org

# References

1. Shepard CW, Simard EP, Finelli L, Riore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. *Epidemiol Rev*. 2006;28:112–25. doi: https://doi.10.1093/epirev/mxj009.
2. Communicable Diseases Network Australia (CDNA). *Hepatitis B CDNA Guidelines for Public Health Units*. Canberra: Australian Government Department of Health and Aged Care; 21 March 2017. [Accessed on 14 September 2023.] Available from: https://www.health.gov.au/sites/default/files/documents/2020/02/hepatitis-b-cdna-national-guidelines-for-public-health-units.pdf.
3. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. *N Engl J Med*. 1979;300(3):101–6. doi: https://doi.10.1056/NEJM197901183000301.
4. Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. *N Engl J Med*. 2004;350(11):1118–29. doi: https://doi.org/10.1056/NEJMra031087.
5. Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. *Med J Aust*. 2019;210(10):462–8. doi: https://doi.org/10.5694/mja2.50160.
6. Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF et al. Risk of hepatitis B virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving rituximab for autoimmune diseases in HBV endemic areas. *Gut Liver*. 2023;17(2):288–98. doi: https://doi.org/10.5009/gnl210551.
7. United States Food and Drug Administration (FDA). *Highlights of prescribing information: rituxan (rituximab)*. Silver Spring: Federal Government of the United States, FDA; October 2012. [Accessed on 14 September 2023.] Available from: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2012/103705s5367s5388lbl.pdf.
8. Gastroenterological Society of Australia (GESA). *Australian consensus recommendations for the management of hepatitis B infection*. Melbourne: GESA; March 2022. [Accessed on 14 September 2023.] Available from: https://www.gesa.org.au/public/13/files/Education%20%26%20Resources/Clinical%20Practice%20Resources/Hep%20B/HBV%20consensus%20Mar%202022%20Updated.pdf.
9. Stamouli M, Gizaris V, Totos G, Papaevangelou G. Decline of hepatitis B infection in Greece. *Eur J Epidemiol*. 1999;15(5):447–9. doi: https://doi.org/10.1023/a:1007539517341.
10. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. *Br J Cancer*. 1999;81(1):69–74. doi: https://doi.org/10.1038/sj.bjc.6690652.
11. The Kirby Institute, Australian Red Cross Blood Service. Safe blood – a focus on education, epidemiology and testing. *Transfusion-transmissible infections in Australia: 2011 Surveillance Report*. Sydney: University of New South Wales, The Kirby Institute/Australian Red Cross Blood Service. [Accessed on 14 September 2023.] Available from: https://www.lifeblood.com.au/sites/default/files/resource-library/2021-12/185.-safe\_blood\_a\_focus\_on\_educationepidemiology\_and\_testing\_8940.pdf.
12. Lewis JD, Enfield KB, Sifri CD. Hepatitis B in healthcare workers: transmission events and guidance for management. *World J Hepatol*. 2015;7(3):488–97. doi: https://doi:10.4254/wjh.v7.i3.488.
13. Communicable Diseases Network Australia (CDNA). CDNA National Guidelines for healthcare workers on managing bloodborne viruses. Canberra: Australian Government Department of Health and Aged Care; October 2019. [Accessed on 14 September 2023.] Available from: https://www.health.gov.au/resources/collections/cdna-national-guidelines-for-healthcare-workers-on-managing-bloodborne-viruses.
14. Etienne S, Vosbeck J, Bernsmeier C, Osthoff M. Prevention of hepatitis B reactivation in patients receiving immunosuppressive therapy: a case series and appraisal of society guidelines. *J Gen Intern Med*. 2023;38(2):490–501. doi: https://doi.10.1007/s11606-022-07806-9.

About Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Protection Policy & Surveillance Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

Disclaimer

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

Enquiries

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Stephanie Williams

Contacts

CDI is produced by:

Health Protection Policy & Surveillance Division, Australian Government Department of Health and Aged Care,  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: [www.health.gov.au/cdi](http://www.health.gov.au/cdi)

Email: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

Submit an Article

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)